Lista de obras -

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability

artículo científico publicado en 2020

Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study

scientific article published on 13 June 2019

Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI

scientific article published on 17 December 2019

Defining the clinical course of multiple sclerosis: the 2013 revisions

artículo científico publicado en 2014

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

artículo científico publicado en 2005

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

artículo científico publicado en 2011

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

artículo científico publicado en 2019

EDSS variability before randomization may limit treatment discovery in primary progressive MS.

artículo científico publicado en 2012

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

artículo científico publicado en 2006

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

article

Evolving expectations around early management of multiple sclerosis

artículo científico publicado en 2010

Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group.

artículo científico publicado en 2005

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

artículo científico publicado en 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

artículo científico publicado en 2016

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis